Registration Strip Icon for smarter Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.

ALGS

Aligos Therapeutics (ALGS)

Aligos Therapeutics Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:ALGS
DateTimeSourceHeadlineSymbolCompany
23/05/202406:05GlobeNewswire Inc.Aligos Therapeutics Announces Six Abstracts Accepted for Presentation at EASL 2024NASDAQ:ALGSAligos Therapeutics Inc
23/05/202406:02Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ALGSAligos Therapeutics Inc
21/05/202422:00GlobeNewswire Inc.Aligos Therapeutics Announces the Completion of Enrollment in the ALG-055009 Phase 2a HERALD Study for the Treatment of MASHNASDAQ:ALGSAligos Therapeutics Inc
16/05/202407:01Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ALGSAligos Therapeutics Inc
08/05/202406:13Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:ALGSAligos Therapeutics Inc
08/05/202406:05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ALGSAligos Therapeutics Inc
08/05/202406:05GlobeNewswire Inc.Aligos Therapeutics Reports Recent Business Progress andĀ First Quarter 2024 Financial ResultsNASDAQ:ALGSAligos Therapeutics Inc
01/05/202406:05GlobeNewswire Inc.Aligos Therapeutics to Announce 1st Quarter 2024 Financial Results on May 7, 2024NASDAQ:ALGSAligos Therapeutics Inc
26/04/202406:05GlobeNewswire Inc.Aligos Therapeutics Presents Positive Clinical Data at ESCMID 2024 from the ALG-097558 Phase 1 StudyNASDAQ:ALGSAligos Therapeutics Inc
25/04/202422:00GlobeNewswire Inc.Aligos Therapeutics Mourns the Passing of MASH Industry Leader Stephen A. Harrison, MDNASDAQ:ALGSAligos Therapeutics Inc
09/04/202422:00GlobeNewswire Inc.Aligos Therapeutics to Participate in the Piper Sandler Spring Biopharma Symposium 2024NASDAQ:ALGSAligos Therapeutics Inc
03/04/202423:00GlobeNewswire Inc.Aligos Therapeutics Announces First Subjects Dosed in the Phase 2a HERALD Study of ALG-055009 in MASH SubjectsNASDAQ:ALGSAligos Therapeutics Inc
27/03/202423:00GlobeNewswire Inc.Aligos Therapeutics Presents Positive Clinical Data at APASL 2024 from ALG-055009 and ALG-000184 Phase 1 StudiesNASDAQ:ALGSAligos Therapeutics Inc
18/03/202423:00GlobeNewswire Inc.Aligos Therapeutics Announces the Initiation of the Phase 2a HERALD Study of ALG-055009 in MASH SubjectsNASDAQ:ALGSAligos Therapeutics Inc
13/03/202407:05GlobeNewswire Inc.Aligos Therapeutics Reports Recent Business Progress andĀ Fourth Quarter and Full Year 2023 Financial ResultsNASDAQ:ALGSAligos Therapeutics Inc
06/03/202408:05GlobeNewswire Inc.Aligos Therapeutics to Announce 4th Quarter 2023 Financial Results on March 12, 2024NASDAQ:ALGSAligos Therapeutics Inc
05/03/202409:44Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ALGSAligos Therapeutics Inc
05/03/202409:42Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ALGSAligos Therapeutics Inc
29/02/202409:35Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ALGSAligos Therapeutics Inc
29/02/202409:33Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ALGSAligos Therapeutics Inc
29/02/202409:31Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ALGSAligos Therapeutics Inc
27/02/202400:00GlobeNewswire Inc.Aligos Therapeutics To Participate in the Leerink Partners Global Biopharma Conference 2024NASDAQ:ALGSAligos Therapeutics Inc
21/02/202400:00GlobeNewswire Inc.Aligos Therapeutics to Host KOL Event to Discuss Phase 2a HERALD Study of ALG-055009 in MASH on March 7, 2024NASDAQ:ALGSAligos Therapeutics Inc
14/02/202400:00GlobeNewswire Inc.Aligos Therapeutics Strengthens Finance Leadership Team with Two New AppointmentsNASDAQ:ALGSAligos Therapeutics Inc
30/01/202423:04Edgar (US Regulatory)Form SC TO-I - Tender offer statement by IssuerNASDAQ:ALGSAligos Therapeutics Inc
25/01/202422:12Edgar (US Regulatory)Form SC TO-C - Written communication relating to an issuer or third partyNASDAQ:ALGSAligos Therapeutics Inc
25/01/202422:06Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ALGSAligos Therapeutics Inc
29/11/202308:01Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:ALGSAligos Therapeutics Inc
23/11/202308:05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ALGSAligos Therapeutics Inc
18/11/202308:38Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:ALGSAligos Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:ALGS